Search Results 121-130 of 35875 for Two-phase

  1. Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 - Mayo Clinic

    The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with ...

  2. Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Mayo Clinic

    Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose. Participation eligibility.

  3. Safusidenib Phase 2 Study in IDH1 Mutant Glioma - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  4. Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA - Mayo Clinic

    Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA · Overview · Participation eligibility · Participating Mayo Clinic ...

  5. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

    About this study. The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), ...

  6. A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease - Mayo Clinic

    Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

  7. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

    TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...

  8. Neurology - Clinical trials

    To accomplish this aim CREST-H will add on to the NINDS-sponsored CREST-2 trial (parallel, outcome-blinded Phase ... stage (PAF), and even at a prodromal stage ( ...

  9. Diabetes prevention: 5 tips for taking control - Mayo Clinic

    1. Lose extra weight · 2. Be more physically active · 3. Eat healthy plant foods · 4. Eat healthy fats · 5. Skip fad diets and make healthier choices.

  10. A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies - Mayo Clinic

    A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies · Overview · Participation eligibility.